General Medicine Division, Walter Reed Army Medical Center, Washington, DC, USA.
BMJ. 2010 Oct 20;341:c5222. doi: 10.1136/bmj.c5222.
To evaluate the efficacy and relative adverse effects of tricyclic antidepressants in the treatment of migraine, tension-type, and mixed headaches.
Meta-analysis.
Medline, Embase, the Cochrane Trials Registry, and PsycLIT. Studies reviewed Randomised trials of adults receiving tricyclics as only treatment for a minimum of four weeks.
Frequency of headaches (number of headache attacks for migraine and number of days with headache for tension-type headaches), intensity of headache, and headache index.
37 studies met the inclusion criteria. Tricyclics significantly reduced the number of days with tension-type headache and number of headache attacks from migraine than placebo (average standardised mean difference -1.29, 95% confidence interval -2.18 to -0.39 and -0.70, -0.93 to -0.48) but not compared with selective serotonin reuptake inhibitors (-0.80, -2.63 to 0.02 and -0.20, -0.60 to 0.19). The effect of tricyclics increased with longer duration of treatment (β=-0.11, 95% confidence interval -0.63 to -0.15; P<0.0005). Tricyclics were also more likely to reduce the intensity of headaches by at least 50% than either placebo (tension-type: relative risk 1.41, 95% confidence interval 1.02 to 1.89; migraine: 1.80, 1.24 to 2.62) or selective serotonin reuptake inhibitors (1.73, 1.34 to 2.22 and 1.72, 1.15 to 2.55). Tricyclics were more likely to cause adverse effects than placebo (1.53, 95% confidence interval 1.11 to 2.12) and selective serotonin reuptake inhibitors (2.22, 1.52 to 3.32), including dry mouth (P<0.0005 for both), drowsiness (P<0.0005 for both), and weight gain (P<0.001 for both), but did not increase dropout rates (placebo: 1.22, 0.83 to 1.80, selective serotonin reuptake inhibitors: 1.16, 0.81 to 2.97).
Tricyclic antidepressants are effective in preventing migraine and tension-type headaches and are more effective than selective serotonin reuptake inhibitors, although with greater adverse effects. The effectiveness of tricyclics seems to increase over time.
评估三环类抗抑郁药治疗偏头痛、紧张型和混合型头痛的疗效和相对不良反应。
荟萃分析。
Medline、Embase、Cochrane 临床试验注册中心和 PsycLIT。研究纳入接受三环类抗抑郁药作为唯一治疗至少 4 周的成年人的随机试验。
头痛发作次数(偏头痛的头痛发作次数和紧张型头痛的头痛天数)、头痛强度和头痛指数。
37 项研究符合纳入标准。三环类抗抑郁药与安慰剂相比,显著减少了紧张型头痛的天数和偏头痛的头痛发作次数(平均标准化均数差值-1.29,95%置信区间-2.18 至-0.39 和-0.70,-0.93 至-0.48),但与选择性 5-羟色胺再摄取抑制剂(SSRIs)相比无差异(-0.80,-2.63 至 0.02 和-0.20,-0.60 至 0.19)。三环类抗抑郁药的疗效随着治疗时间的延长而增加(β=-0.11,95%置信区间-0.63 至-0.15;P<0.0005)。三环类抗抑郁药也更有可能将头痛强度降低至少 50%,与安慰剂(紧张型:相对风险 1.41,95%置信区间 1.02 至 1.89;偏头痛:1.80,1.24 至 2.62)或选择性 5-羟色胺再摄取抑制剂(1.73,1.34 至 2.22 和 1.72,1.15 至 2.55)相比。三环类抗抑郁药比安慰剂(1.53,95%置信区间 1.11 至 2.12)和选择性 5-羟色胺再摄取抑制剂(2.22,1.52 至 3.32)更易引起不良反应,包括口干(两者均 P<0.0005)、嗜睡(两者均 P<0.0005)和体重增加(两者均 P<0.001),但不会增加停药率(安慰剂:1.22,0.83 至 1.80,选择性 5-羟色胺再摄取抑制剂:1.16,0.81 至 2.97)。
三环类抗抑郁药在预防偏头痛和紧张型头痛方面有效,且比选择性 5-羟色胺再摄取抑制剂更有效,但不良反应更多。三环类抗抑郁药的疗效似乎随时间增加而增加。